Evidence map›Paper›PMID 34896649›Full record

ArticleTravel medicine and infectious disease

Differentiating COVID-19 and dengue from other febrile illnesses in co-epidemics: Development and internal validation of COVIDENGUE scores.

Patrick Gérardin, Olivier Maillard, Léa Bruneau, Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti, Cécile Levin

Abstract read
In one paragraph

Article in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Dengue Mimickers: Which Clinical Conditions Can Resemble Dengue Fever?Revista da Sociedade Brasileira de Medicina Tropical · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patrick GérardinCentre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion. Electronic address: patrick.gerardin@chu-reunion.fr.
Olivier MaillardCentre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Léa BruneauDepartment of Public Health and Research Support, Centre Hospitalier Universitaire de La Réunion, Saint Denis, Reunion.
Frédéric AccotCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Florian LegrandCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; City to Hospital Outpatient Clinic for the Care of COVID-19, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Patrice PoubeauCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; City to Hospital Outpatient Clinic for the Care of COVID-19, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Rodolphe ManaquinCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; City to Hospital Outpatient Clinic for the Care of COVID-19, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Fanny AndryCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; City to Hospital Outpatient Clinic for the Care of COVID-19, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Antoine BertolottiCentre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; COVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.
Cécile LevinCOVID-19 Testing Centre, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion; City to Hospital Outpatient Clinic for the Care of COVID-19, Centre Hospitalier Universitaire de La Réunion, Saint Pierre, Reunion.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe purpose of this cohort study was to develop two scores able to differentiate coronavirus 2019 (COVID-19) from dengue and other febrile illnesses (OFIs).

methodsAll subjects suspected of COVID-19 who attended the SARS-CoV-2 testing center of Saint-Pierre hospital, Reunion, between March 23 and May 10, 2020, were assessed for identifying predictors of both infectious diseases from a multinomial logistic regression model. Two scores were developed after weighting the odd ratios then validated by bootstrapping.

resultsOver 49 days, 80 COVID-19, 60 non-severe dengue and 872 OFIs were diagnosed. The translation of the best fit model yielded two scores composed of 11 criteria: contact with a COVID-19 positive case (+3 points for COVID-19; 0 point for dengue), return from travel abroad within 15 days (+3/-1), previous individual episode of dengue (+1/+3), active smoking (-3/0), body ache (0/+5), cough (0/-2), upper respiratory tract infection symptoms (-1/-1), anosmia (+7/-1), headache (0/+5), retro-orbital pain (-1/+5), and delayed presentation (>3 days) to hospital (+1/0). The area under the receiver operating characteristic curve was 0.79 (95%CI 0.76-0.82) for COVID-19 score and 0.88 (95%CI 0.85-0.90) for dengue score. Calibration was satisfactory for COVID-19 score and excellent for dengue score. For predicting COVID-19, sensitivity was 97% at the 0-point cut-off and specificity 99% at the 10-point cut-off. For predicting dengue, sensitivity was 97% at the 3-point cut-off and specificity 98% at the 11-point cut-off.

conclusionsCOVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue from OFIs in the context of SARS-CoV-2 testing center during a co-epidemic.

Indexed as

COVID-19DengueEpidemicsCohort StudiesCOVID-19 TestingHumansSARS-CoV-2ArbovirusCohort studyCOVID-19DenguePrediction modelSARS-CoV-2

Identifiers

PMID34896649
PMCPMC8656151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.